Technical analysis of Arcus Biosciences, Inc. (RCUS): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Price Performance
| 1 month | -25.57% |
| 3 months | -36.84% |
| Year-to-date | -23.67% |
| 1 year | -7.76% |
| 3 years | +11.12% |
| 5 years | -49.68% |
52-Week Range
| 52-week High | $31.74 |
| 52-week Low | $17.43 |
| Avg Volume (90d) | 1.6M |
Technical Indicators
| SMA 50 | $24.98 |
| SMA 200 | $24.66 |
| Beta | 0.86 |
| 30-day Volatility (annualised) | 77.0% |
| Price vs SMA 50 | -27.2% |
| Price vs SMA 200 | -26.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $23.83 | |
| 2026-01 | $21.04 | -11.7% |
| 2026-02 | $20.37 | -3.2% |
| 2026-03 | $21.60 | +6.0% |
| 2026-04 | $25.50 | +18.1% |
| 2026-05 | $25.34 | -0.6% |
| 2026-06 | $30.83 | +21.7% |
| 2026-07 | $28.19 | -8.6% |
| 2026-08 | $29.28 | +3.9% |
| 2026-09 | $25.83 | -11.8% |
| 2026-10 | $18.19 | -29.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-04 | $-0.89 | $8M |
| 2026-08-05 | $-0.89 | $22M |
| 2026-05-05 | $-0.92 | $29M |
| 2026-02-25 | $-1.11 | $36M |
| 2025-10-28 | $-1.33 | $25M |
| 2025-08-06 | $-1.14 | $32M |
| 2025-05-06 | $-1.02 | $37M |
Price
| Price | $18.19 (closing price, October 30, 2026) |
| Market Cap | $2.3B |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | 4.94 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.25 |
| Current Ratio | 3.82 |
| Piotroski F-Score | 0 |
| Altman Z-Score | 1.11 |